Fibrosis, a non-physiological wound healing in multiple organs, is associated with end-stage pathological symptoms of a wide variety of vascular injury and inflammation related diseases. In response to chemical, immunological and physical insults, the body’s defense system and matrix synthetic machinery respond to healing the wound and maintain tissue homeostasis. However, uncontrolled wound healing leads to scarring or fibrosis, a pathological condition characterized by excessive synthesis and accumulation of extracellular matrix proteins, loss of tissue homeostasis and organ failure. Understanding the actual cause of pathological wound healing and identification of igniter(s) of fibrogenesis would be helpful to design novel therapeutic approaches to control pathological wound healing and to prevent fibrosis related morbidity and mortality. In this article, we review the significance of a few key cytokines (TGF-β, IFN-γ, IL-10) transcriptional activators (Sp1, Egr-1, Smad3), repressors (Smad7, Fli-1, PPAR-γ, p53, Klotho) and epigenetic modulators (acetyltransferase, methyltransferases, deacetylases, microRNAs) involved in major matrix protein collagen synthesis under pathological stage of wound healing, and the potentiality of these regulators as therapeutic targets for fibrosis treatment. The significance of endothelial to mesenchymal transition (EndMT) and senescence, two newly emerged fields in fibrosis research, has also been discussed.
EllmersLJ. The role of transforming growth factor-β in cardiac fibrosis. Curr Enzyme Inhib2010; 6: 78–86.
7.
LeaskA. Sticking it to scleroderma: potential therapies blocking elevated adhesive and contractile signaling. Curr Enzyme Inhib2010; 6: 97–104.
8.
MatsuzakiK. Smad3-mediated signals showing similarities and differences between epithelial and mesenchymal cells in human chronic liver diseases. Curr Enzyme Inhib2010; 6: 57–66.
YangHCZuoYFogoAB. Transforming growth factor-beta and the kidney: what we know and what we can do?Curr Enzyme Inhib2010; 6: 87–96.
11.
JeanssonMGawlikAAndersonGLiCKerjaschkiDHenkelmanMQuagginSE. Angiopoietin-1 is essential in mouse vasculature during development and in response to injury. J Clin Invest2011; 121: 2278–89.
12.
GhoshAK. Factors involved in Type I collagen gene expression: implication in scleroderma. Exp Biol Med2002; 227: 301–14.
13.
GhoshAKVargaJ. The transcriptional coactivator and acetyltransferase p300 in fibroblast biology and fibrosis. J Cell Physiol2007; 213: 663–71.
14.
van MeeterenLAten DijkeP. Regulation of endothelial cell plasticity by TGF-β. Cell Tissue Res2012; 347: 177–86.
15.
GhoshAKVaughanDE. Fibrosis: is it a coactivator disease?Front Biosci2012; E4: 1556–60.
Schultz JelJWittSAGlascockBJ. TGF-beta1 mediates the hypertrophic cardiomyocyte growth induced by angiotensin II. J Clin Invest2002; 109: 787–96.
26.
InagakiYTruterSRamirezF. Transforming growth factor-beta stimulates alpha 2(I) collagen gene expression through a cis-acting element that contains an Sp1-binding site. J Biol Chem1994; 269: 14828–34.
27.
ChungKYAgarwalAUittoJMauvielA. An AP-1 binding sequence is essential for regulation of the human alpha2(I) collagen (COL1A2) promoter activity by transforming growth factor-beta. J Biol Chem1996; 271: 3272–8.
28.
NakaoAImamuraTSouchelnytskyiSKawabataMIshisakiAOedaETamakiKHanaiJHeldinCHMiyazonoKten DijkeP. TGF-beta receptor-mediated signalling through Smad2, Smad3 and Smad4. EMBO J1997; 16: 5353–62.
29.
NakaoAAfrakhteMMorénANakayamaTChristianJLHeuchelRItohSKawabataMHeldinNEHeldinCHten DijkeP. Identification of Smad7, a TGFbeta-inducible antagonist of TGF-beta signalling. Nature1997; 389: 631–5.
30.
FengXHZhangYWuRYDerynckR. The tumor suppressor Smad4/DPC4 and transcriptional adaptor CBP/p300 are coactivators for smad3 in TGF-beta-induced transcriptional activation. Genes Dev1998; 12: 2153–63.
31.
TopperJNDiChiaraMRBrownJDWilliamsAJFalbDCollinsTGimbroneMA Jr. CREB binding protein is a required coactivator for Smad-dependent, transforming growth factor beta transcriptional responses in endothelial cells. Proc Natl Acad Sci U S A1998; 95: 9506–11.
32.
PouponnotCJayaramanLMassaguéJ. Physical and functional interaction of SMADs and p300/CBP. J Biol Chem1998; 273: 22865–68.
33.
JanknechtRWellsNJHunterT. TGF-beta-stimulated cooperation of Smad proteins with the coactivators CBP/p300. Genes Dev1998; 12: 2114–19.
34.
ChenSJYuanWMoriYLevensonATrojanowskaMVargaJ. Stimulation of type I collagen transcription in human skin fibroblasts by TGF-β: involvement of Smad3. J Invest Dermatol1999; 112: 49–57.
35.
MoriYChenSJVargaJ. Modulation of endogenous Smad expression in normal skin fibroblasts by transforming growth factor-beta. Exp Cell Res2000; 258: 374–83.
36.
GhoshAKYuanWMoriYVargaJ. Smad-dependent stimulation of type I collagen gene expression in human skin fibroblasts by TGF-β involves functional cooperation with p300/CBP transcriptional coactivators. Oncogene2000; 19: 3546–55.
37.
GhoshAKYuanWMoriYChenSJVargaJ. Antagonistic regulation of type I collagen gene expression by interferon-γ and transforming growth factor-β: integration at the level of p300/CBP transcriptional coactivators. J Biol Chem2001; 276: 11041–48.
38.
GhoshAKBhattacharyyaSVargaJ. The tumor suppressor p53 abrogates Smad-dependent collagen gene induction in mesenchymal cells. J Biol Chem2004; 279: 47455–63.
39.
GhoshAKBhattacharyyaSWeiJKimSBarakYMoriYVargaJ. Peroxisome proliferator-activated receptor-gamma abrogates Smad-dependent collagen stimulation by targeting the p300 transcriptional coactivator. FASEB J2009; 23: 2968–77.
40.
BhattacharyyaSGhoshAKPannuJMoriYTakagawaSChenGTrojanowskaMGilliamACVargaJ. Fibroblasts expression of the coactivator p300 governs the intensity of profibrotic response to TGF-β. Arthritis Rheum2005; 52: 1248–58.
41.
ZhangWOuJInagakiYGreenwelPRamirezF. Synergistic cooperation between Sp1 and Smad3/Smad4 mediates transforming growth factor beta1 stimulation of alpha 2(I)-collagen (COL1A2) transcription. J Biol Chem2000; 275: 39237–45.
ZhaoJShiWWangYLChenHBringasP JrDattoMBFrederickJPWangXFWarburtonD. Smad3 deficiency attenuates bleomycin-induced pulmonary fibrosis in mice. Am J Physiol Lung Cell Mol Physiol2002; 282: L585–93.
44.
LakosGTakagawaSChenSJFerreiraAMHanGMasudaKWangXJDiPietroLAVargaJ. Targeted disruption of TGF-beta/Smad3 signaling modulates skin fibrosis in a mouse model of scleroderma. Am J Pathol2004; 165: 203–17.
45.
TanWQGaoZJXuJHYaoHP. Inhibiting scar formation in vitro and in vivo by adenovirus-mediated mutant Smad4: a preliminary report. Exp Dermatol2011; 20: 119–24.
46.
MengXMHuangXRXiaoJChungACQinWChenHYLanHY. Disruption of Smad4 impairs TGF-β/Smad3 and Smad7 transcriptional regulation during renal inflammation and fibrosis in vivo and in vitro. Kidney Int2012; 81: 266–79.
47.
LatellaGVetuschiASferraRCatittiVD'AngeloAZanninelliGFlandersKCGaudioE. Targeted disruption of Smad3 confers resistance to the development of dimethylnitrosamine-induced hepatic fibrosis in mice. Liver Int2009; 29: 997–1009.
48.
MoriYChenSJVargaJ. Expression and regulation of intracellular SMAD signaling in scleroderma skin fibroblasts. Arthritis Rheum2003; 48: 1964–78.
49.
IhnHYamaneKAsanoYJinninMTamakiK. Constitutively phosphorylated Smad3 interacts with Sp1 and p300 in scleroderma fibroblasts. Rheumatology (Oxf)2006; 45: 157–65.
50.
MassaguéJ. TGF-beta signal transduction. Annu Rev Biochem1998; 67: 753–91.
51.
AsadullahKSterryWVolkHD. Interleukin-10 therapy – review of a new approach. Pharmacol Rev2003; 55: 241–69.
52.
SongZBarveSChenTNelsonWUriarteSHillDMcClainC. S-adenosylmethionine (AdoMet) modulates endotoxin stimulated interleukin-10 production in monocytes. Am J Physiol Gastrointest Liver Physiol2003; 284: G949–55.
53.
SafadiROhtaMAlvarezCEFielMIBansalMMehalWZFriedmanSL. Immune stimulation of hepatic fibrogenesis by CD8 cells and attenuation by transgenic interleukin-10 from hepatocytes. Gastroenterology2004; 127: 870–82.
54.
ZhangLJZhengWDChenYXHuangYHChenZXZhangSJShiMNWangXZ. Antifibrotic effects of interleukin-10 on experimental hepatic fibrosis. Hepatogastroenterology2007; 54: 2092–8.
55.
Nowatzky J, Knorr A, Hirth-Dietrich C, Siegling A, Volk HD, Limmer A, Knolle P, Weber O. Inactivated Orf virus (Parapoxvirus ovis) elicits antifibrotic activity in models of liver fibrosis. Hepatol Res Epub ahead of print 13 September 2012. DOI: 10.1111/j.1872-034X.2012.01086.x.
56.
García-PrietoEGonzález-LópezACabreraSAstudilloAGutiérrez-FernándezAFanjul-FernandezMBatalla-SolísEPuenteXSFueyoALópez-OtínCAlbaicetaGM. Resistance to bleomycin-induced lung fibrosis in MMP-8 deficient mice is mediated by interleukin-10. PLoS One2010; 5: e13242–e13242.
57.
El-DemerdashE. Anti-inflammatory and antifibrotic effects of methyl palmitate. Toxicol Appl Pharmacol2011; 254: 238–44.
58.
Gotoh K, Inoue M, Masaki T, Chiba S, Shiraishi K, Shimasaki T, Matsuoka K, Ando H, Fujiwara K, Fukunaga N, Aoki K, Nawata T, Katsuragi I, Kakuma T, Seike M, Yoshimatsu H. Obesity-related chronic kidney disease is associated with spleen-derived IL-10. Nephrol Dial Transplant 2012:1–10.
59.
VermaSKKrishnamurthyPBarefieldDSinghNGuptaRLambersEThalMMackieAHoxhaERamirezVQinGSadayappanSGhoshAKKishoreR. Interleukin-10 treatment attenuates pressure overload-induced hypertrophic remodeling and improves heart function via signal transducers and activators of transcription 3-dependent inhibition of nuclear factor-κB. Circulation2012; 126: 418–29.
60.
SuhYGKimJKByunJSYiHSLeeYSEunHSKimSYHanKHLeeKSDuesterGFriedmanSLJeongWI. CD11b(+) Gr1(+) bone marrow cells ameliorate liver fibrosis by producing interleukin-10 in mice. Hepatology2012; 56: 1902–12.
61.
RachmawatiHBeljaarsLReker-SmitCBakkerHIVan Loenen-WeemaesAMLub-De HoogeMNPoelstraK. Intravenous administration of recombinant human IL-10 suppresses the development of anti-thy 1-induced glomerulosclerosis in rats. PDA J Pharm Sci Technol2011; 65: 116–30.
62.
SunLLouieMCVannellaKMWilkeCALeVineAMMooreBBShanleyTP. New concepts of IL-10-induced lung fibrosis: fibrocyte recruitment and M2 activation in a CCL2/CCR2 axis. Am J Physiol Lung Cell Mol Physiol2011; 300: L341–53.
63.
HasegawaMFujimotoMKikuchiKTakeharaK. Elevated serum levels of interleukin 4 (IL-4), IL-10, and IL-13 in patients with systemic sclerosis. J Rheumatol1997; 24: 328–32.
64.
SatoSHasegawaMTakeharaK. Serum levels of interleukin-6 and interleukin-10 correlate with total skin thickness score in patients with systemic sclerosis. J Dermatol Sci2001; 27: 140–46.
65.
MitchellTJJohnS. Signal transducer and activator of transcription (STAT) signalling and T-cell lymphomas. Immunology2005; 114: 301–12.
66.
VargaJOlsenAHerhalJConstantineGRosenbloomJJimenezSA. Interferon-gamma reverses the stimulation of collagen but not fibronectin gene expression by transforming growth factor-beta in normal human fibroblasts. Eur J Clin Invest1990; 20: 487–93.
67.
KähäriVMChenYQSuMWRamirezFUittoJ. Tumor necrosis factor-alpha and interferon-gamma suppress the activation of human type I collagen gene expression by transforming growth factor-beta 1. Evidence for two distinct mechanisms of inhibition at the transcriptional and posttranscriptional levels. J Clin Invest1990; 86: 1489–95.
68.
JaffeHAGaoZMoriYLiLVargaJ. Selective inhibition of collagen gene expression in fibroblasts by an interferon-gamma transgene. Exp Lung Res1999; 25: 199–215.
69.
DooleySSaidHMGressnerAMFloegeJEn-NiaAMertensPR. Y-box protein-1 is the crucial mediator of antifibrotic interferon-gamma effects. J Biol Chem2006; 281: 1784–95.
70.
KimHJSongSBChoiJMKimKMChoBKChoDHParkHJ. IL-18 downregulates collagen production in human dermal fibroblasts via the ERK pathway. J Invest Dermatol2010; 130: 706–15.
71.
GhoshAKBhattacharyyaSMoriYVargaJ. Inhibition of collagen gene expression by interferon-gamma: novel role of the CCAAT/enhancer binding protein beta (C/EBPbeta). J Cell Physiol2006; 207: 251–60.
72.
GiannopoulouMIszkulaSCDaiCTanXYangJMichalopoulosGKLiuY. Distinctive role of Stat3 and Erk-1/2 activation in mediating interferon-gamma inhibition of TGF-beta1 action. Am J Physiol Renal Physiol2006; 290: F1234–40.
73.
Sherriff-TadanoROhtaAMoritoFMitamuraMHarutaYKoaradaSTadaYNagasawaKOzakiI. Antifibrotic effects of hepatocyte growth factor on scleroderma fibroblasts and analysis of its mechanism. Mod Rheumatol2006; 16: 364–71.
74.
GurujeyalakshmiGGiriSN. Molecular mechanisms of antifibrotic effect of interferon gamma in bleomycin-mouse model of lung fibrosis: downregulation of TGF-beta and procollagen I and III gene expression. Exp Lung Res1995; 21: 791–808.
75.
ChenYChenJDongJLiuW. Antifibrotic effect of interferon gamma in silicosis model of rat. Toxicol Lett2005; 155: 353–60.
WengHLCaiWMLiuRH. Animal experiment and clinical study of effect of gamma-interferon on hepatic fibrosis. World J Gastroenterol2001; 7: 42–8.
78.
EmmezHKardesODoguluFKurtGMemisLBaykanerMK. Role of antifibrotic cytokine interferon-gamma in the prevention of postlaminectomy peridural fibrosis in rats. Neurosurgery2008; 62: 1351–57.
79.
MillerCHMaherSGYoungHA. Clinical use of interferon-gamma. Ann N Y Acad Sci2009; 1182: 69–79.
80.
D'AlessioJAWrightKJTjianR. Shifting players and paradigms in cell-specific transcription. Mol Cell2009; 36: 924–31.
81.
GoodrichJATjianR. Unexpected roles for core promoter recognition factors in cell-type-specific transcription and gene regulation. Nat Rev Genet2010; 11: 549–58.
82.
DynanWSTjianR. Isolation of transcription factors that discriminate between different promoters recognized by RNA polymerase II. Cell1983; 32: 669–80.
83.
BriggsMRKadonagaJTBellSPTjianR. Purification and biochemical characterization of the promoter-specific transcription factor, Sp1. Science1986; 234: 47–52.
84.
RevyakinAZhangZColemanRALiYInouyeCLucasJKParkSRChuSTjianR. Transcription initiation by human RNA polymerase II visualized at single-molecule resolution. Genes Dev2012; 26: 1691–702.
85.
TamakiTOhnishiKHartlCLeRoyECTrojanowskaM. Characterization of a GC-rich region containing Sp1 binding site(s) as a constitutive responsive element of the alpha 2(I) collagen gene in human fibroblasts. J Biol Chem1995; 270: 4299–304.
86.
GreenwelPInagakiYHuWWalshMRamirezF. Sp1 is required for the early response of alpha2(I) collagen to transforming growth factor-beta1. J Biol Chem1997; 272: 19738–45.
87.
ChenSJArtlettCMJimenezSAVargaJ. Modulation of human alpha1(I) procollagen gene activity by interaction with Sp1 and Sp3 transcription factors in vitro. Gene1998; 215: 101–10.
88.
VerrecchiaFRossertJMauvielA. Blocking sp1 transcription factor broadly inhibits extracellular matrix gene expression in vitro and in vivo: implications for the treatment of tissue fibrosis. J Invest Dermatol2001; 116: 755–63.
89.
GoffinLSeguin-EstévezQAlvarezMReithWChizzoliniC. Transcriptional regulation of matrix metalloproteinase-1 and collagen 1A2 explains the anti-fibrotic effect exerted by proteasome inhibition in human dermal fibroblasts. Arthritis Res Ther2010; 12: R73–R73.
90.
ZhuLGaoDYangJLiM. Characterization of the phenotype of high collagen-producing fibroblast clones in systemic sclerosis, using a new modified limiting-dilution method. Clin Exp Dermatol2012; 37: 395–403.
91.
ChaeYMParkKKLeeIKKimJKKimCHChangYC. Ring-Sp1 decoy oligonucleotide effectively suppresses extracellular matrix gene expression and fibrosis of rat kidney induced by unilateral ureteral obstruction. Gene Ther2006; 13: 430–9.
92.
KassimatisTINomikosAGiannopoulouILymperopoulosAMoutzourisDAVarakisINakopoulouL. Transcription factor Sp1 expression is upregulated in human glomerulonephritis: correlation with pSmad2/3 and p300 expression and renal injury. Ren Fail2010; 32: 243–53.
93.
Kim KH, Park JH, Lee WR, Park JS, Kim HC, Park KK. The inhibitory effect of chimeric decoy oligodeoxynucleotide against NF-κB and Sp1 in renal interstitial fibrosis. J Mol Med (Berl) Epub ahead of print 1 November 2012 DOI: 10.1007/500109-012-0972-2.
94.
LiuGXLiYQHuangXRWeiLChenHYShiYJHeuchelRLLanHY. Disruption of Smad7 promotes ANG II-mediated renal inflammation and fibrosis via Sp1-TGF-β/Smad3-NF.κB-dependent mechanisms in mice. PLoS One2013; 8: e53573–e53573.
95.
ParkJHJoJHKimKHKimSJLeeWRParkKKParkJB. Antifibrotic effect through the regulation of transcription factor using ring type-Sp1 decoy oligodeoxynucleotide in carbon tetrachloride-induced liver fibrosis. J Gene Med2009; 11: 824–33.
96.
ChenHZhouYChenKQAnGJiSYChenQK. Anti-fibrotic effects via regulation of transcription factor Sp1 on hepatic stellate cells. Cell Physiol Biochem2012; 29: 51–60.
97.
García-RuizIGómez-IzquierdoEDíaz-SanjuánTGrauMSolís-MuñozPMuñoz-YagüeTSolís-HerruzoJA. Sp1 and Sp3 transcription factors mediate leptin-induced collagen α1(I) gene expression in primary culture of male rat hepatic stellate cells. Endocrinology2012; 153: 5845–56.
98.
LuzinaIGTsymbalyukNChoiJHasdayJDAtamasSP. CCL18-stimulated upregulation of collagen production in lung fibroblasts requires Sp1 signaling and basal Smad3 activity. J Cell Physiol2006; 206: 221–8.
99.
KumYSKimKHParkTIOhHKChoCHParkJBChangYCParkJHLeeKGParkKK. Antifibrotic effect via the regulation of transcription factor Sp1 in lung fibrosis. Biochem Biophys Res Commun2007; 363: 368–74.
100.
LuchsingerLLPatenaudeCASmithBDLayneMD. Myocardin-related transcription factor-A complexes activate type I collagen expression in lung fibroblasts. J Biol Chem2011; 286: 44116–44125.
101.
SilvermanESCollinsT. Pathways of Egr-1-mediated gene transcription in vascular biology. Am J Pathol1999; 154: 665–70.
102.
GhoshAKBhattacharyyaSLafyatisRFarinaGYuJThimmapayaBWeiJVargaJ. p300 is elevated in systemic sclerosis and its expression is positively regulated by TGF-β: epigenetic feed-forward amplification of fibrosis. J Invest Dermatol2013; 133: 1302–10.
103.
YanSFFujitaTLuJOkadaKShan ZouYMackmanNPinskyDJSternDM. Egr-1, a master switch coordinating upregulation of divergent gene families underlying ischemic stress. Nat Med2000; 6: 1355–61.
104.
HuangZLiHGuoFJiaQZhangYLiuXShiG. Egr-1, the potential target of calcium channel blockers in cardioprotection with ischemia/reperfusion injury in rats. Cell Physiol Biochem2009; 24: 17–24.
105.
ZhangYMShiGGTangZZhengJHLiWQGuoFXJiaQY. Effects of N-n-butyl haloperidol iodide on myocardial ischemia/reperfusion injury and Egr-1 expression in rat. Acta Biochim Biophys Sin2006; 38: 435–41.
106.
NakamuraHIsakaYTsujieMRupprechtHDAkagiYUedaNImaiEHoriM. Introduction of DNA enzyme for Egr-1 into tubulointerstitial fibroblasts by electroporation reduced interstitial alpha-smooth muscle actin expression and fibrosis in unilateral ureteral obstruction (UUO) rats. Gene Ther2002; 9: 495–502.
107.
LeeCGChoSJKangMJChapovalSPLeePJNoblePWYehualaeshetTLuBFlavellRAMilbrandtJHomerRJEliasJA. Early growth response gene 1-mediated apoptosis is essential for transforming growth factor beta1-induced pulmonary fibrosis. J Exp Med2004; 200: 377–89.
108.
ChenSJNingHIshidaWSodin-SemrlSTakagawaSMoriYVargaJ. The early-immediate gene EGR-1 is induced by transforming growth factor-beta and mediates stimulation of collagen gene expression. J Biol Chem2006; 281: 21183–97.
109.
WuMMelichianDSde la GarzaMGrunerKBhattacharyyaSBarrLNairAShahraraSSpornPHMustoeTATourtellotteWGVargaJ. Essential roles for early growth response transcription factor Egr-1 in tissue fibrosis and wound healing. Am J Pathol2009; 175: 1041–55.
110.
PritchardMTNagyLE. Hepatic fibrosis is enhanced and accompanied by robust oval cell activation after chronic carbon tetrachloride administration to Egr-1-deficient mice. Am J Pathol2010; 176: 2743–52.
111.
PritchardMTMalinakRNNagyLE. Early growth response (EGR)-1 is required for timely cell-cycle entry and progression in hepatocytes after acute carbon tetrachloride exposure in mice. Am J Physiol Gastrointest Liver Physiol2011; 300: G1124–31.
112.
SullivanBPCuiWCoppleBLLuyendykJP. Early growth response factor-1 limits biliary fibrosis in a model of xenobiotic-induced cholestasis in mice. Toxicol Sci2012; 126: 267–74.
113.
NakaoAFujiiMMatsumuraRKumanoKSaitoYMiyazonoKIwamotoI. Transient gene transfer and expression of Smad7 prevents bleomycin-induced lung fibrosis in mice. J Clin Invest1999; 104: 5–11.
114.
ChungACDongYYangWZhongXLiRLanHY. Smad7 suppresses renal fibrosis via altering expression of TGF-β/Smad3-regulated microRNAs. Mol Ther2013; 21: 388–98.
115.
TangLXHeRHYangGTanJJZhouLMengXMHuangXRLanHY. Asiatic acid inhibits liver fibrosis by blocking TGF-beta/Smad signaling in vivo and in vitro. PLoS One2012; 7: e31350–e31350.
116.
DooleySHamzaviJBreitkopfKSaidHMLorenzenJTen DijkePGressnerAM. Smad7 prevents activation of hepatic stellate cells and liver fibrosis in rats. Gastroenterology2003; 125: 178–91.
117.
WangBLiWChenYWangYSunCChenYLuHFanJLiD. Coexpression of Smad7 and UPA attenuates carbon tetrachloride-induced rat liver fibrosis. Med Sci Monit2012; 18: BR394–401.
118.
YaoQYXuBLWangJYLiuHCZhangSCTuCT. Inhibition by curcumin of multiple sites of the transforming growth factor-beta1 signalling pathway ameliorates the progression of liver fibrosis induced by carbon tetrachloride in rats. BMC Complement Altern Med2012; 12: 156–156.
119.
DongCZhuSWangT. Deficient Smad7 expression: a putative molecular defect in scleroderma. Proc Natl Acad Sci U S A2002; 99: 3908–13.
120.
ZhuHLiYQuS. MicroRNA expression abnormalities in limited cutaneous scleroderma and diffuse cutaneous scleroderma. J Clin Immunol2012; 32: 514–22.
121.
LanHYMuWTomitaNYoonWLiZAlvarezRJten DijkePWhiteBWigleyFM. Inhibition of renal fibrosis by gene transfer of inducible Smad7 using ultrasound-microbubble system in rat UUO model. J Am Soc Nephrol2003; 14: 1535–48.
122.
FukasawaHYamamotoTTogawaAOhashiNFujigakiYOdaTUchidaCKitagawaKHattoriTSuzukiSKitagawaMHishidaA. Down-regulation of Smad7 expression by ubiquitin-dependent degradation contributes to renal fibrosis in obstructive nephropathy in mice. Proc Natl Acad Sci U S A2004; 101: 8687–92.
123.
HouCCWangWHuangXRFuPChenTHSheikh-HamadDLanHY. Ultrasound-microbubble-mediated gene transfer of inducible Smad7 blocks transforming growth factor-beta signaling and fibrosis in rat remnant kidney. Am J Pathol2005; 166: 761–71.
WangZFWangNPHarmoucheSPhilipTPangXFBaiFZhaoZQ. Postconditioning promotes the cardiac repair through balancing collagen degradation and synthesis after myocardial infarction in rats. Basic Res Cardiol2013; 108: 318–318.
128.
WangNPWangZFTootleSPhilipTZhaoZQ. Curcumin promotes cardiac repair and ameliorates cardiac dysfunction following myocardial infarction. Br J Pharmacol2012; 167: 1550–62.
129.
Czuwara-LadykowskaJShirasakiFJackersPWatsonDKTrojanowskaM. Fli-1 inhibits collagen type I production in dermal fibroblasts via an Sp1-dependent pathway. J Biol Chem2001; 276: 20839–48.
130.
KuboMCzuwara-LadykowskaJMoussaOMarkiewiczMSmithESilverRMJablonskaSBlaszczykMWatsonDKTrojanowskaM. Persistent down-regulation of Fli1, a suppressor of collagen transcription, in fibrotic scleroderma skin. Am J Pathol2003; 163: 571–81.
131.
AsanoYCzuwaraJTrojanowskaM. Transforming growth factor-beta regulates DNA binding activity of transcription factor Fli1 by p300/CREB-binding protein-associated factor-dependent acetylation. J Biol Chem2007; 282: 34672–83.
132.
Van BeekJPKennedyLRockelJSBernierSMLeaskA. The induction of CCN2 by TGFbeta1 involves Ets-1. Arthritis Res Ther2006; 8: R36–R36.
133.
LiuSTaghaviRLeaskA. Connective tissue growth factor is induced in bleomycin-induced skin scleroderma. J Cell Commun Signal2010; 4: 25–30.
134.
NakerakantiSSKapanadzeBYamasakiMMarkiewiczMTrojanowskaM. Fli1 and Ets1 have distinct roles in connective tissue growth factor/CCN2 gene regulation and induction of the profibrotic gene program. J Biol Chem2006; 281: 25259–69.
135.
ElkarehJPeriyasamySMShidyakAVettethSSchroederJRajuVHaririIMEl-OkdiNGuptaSFedorovaLLiuJFedorovaOVKahalehMBXieZMalhotraDWatsonDKBagrovAYShapiroJI. Marinobufagenin induces increases in procollagen expression in a process involving protein kinase C and Fli-1: implications for uremic cardiomyopathy. Am J Physiol Renal Physiol2009; 296: F1219–26.
136.
NikitinaERMikhailovAVNikandrovaESFrolovaEVFadeevAVShmanVVShilovaVYTapilskayaNIShapiroJIFedorovaOVBagrovAY. In preeclampsia endogenous cardiotonic steroids induce vascular fibrosis and impair relaxation of umbilical arteries. J Hypertens2011; 29: 769–76.
137.
HallerSTKennedyDJShidyakAMalhotraDFedorovaOVShapiroJIBagrovAY. Monoclonal antibody against marinobufagenin reverses cardiac fibrosis in rats with chronic renal failure. Am J Hypertens2012; 25: 690–6.
138.
TontonozPHuESpiegelmanBM. Stimulation of adipogenesis in fibroblasts by PPAR γ2, a lipid-activated transcription factor. Cell1994; 79: 1147–56.
139.
MurphyGJHolderJC. PPAR-gamma agonists: therapeutic role in diabetes, inflammation and cancer. Trends Pharmacol Sci2000; 21: 469–74.
140.
LehrkeMLazarMA. The many faces of PPARgamma. Cell2005; 123: 993–9.
141.
BergerJMollerDE. The mechanisms of action of PPARs. Annu Rev Med2002; 53: 409–35.
142.
GhoshAKBhattacharyyaSLakosGChenSJMoriYVargaJ. Disruption of transforming growth factor beta signaling and profibrotic responses in normal skin fibroblasts by peroxisome proliferator-activated receptor gamma. Arthritis Rheum2004; 50: 1305–18.
143.
GhoshAKWeiJWuMVargaJ. Constitutive Smad signaling and Smad-dependent collagen gene expression in mouse embryonic fibroblasts lacking peroxisome proliferator-activated receptor-gamma. Biochem Biophys Res Commun2008; 374: 231–6.
144.
RouthREJohnsonJHMcCarthyKJ. Troglitazone suppresses the secretion of type I collagen by mesangial cells in vitro. Kidney Int2002; 61: 1365–76.
145.
ZhengFFornoniAElliotSJGuanYBreyerMDStrikerLJ. Upregulation of type I collagen by TGF-β in mesangial cells is blocked by PPARγ activation. Am J Physiol Renal Physiol2002; 282: F639–48.
146.
GalliACrabbDWCeniESalzanoRMelloTSvegliati-BaroniG. Antidiabetic thiazolidinediones inhibit collagen synthesis and hepatic stellate cell activation in vivo and in vitro. Gastroenterology2002; 122: 1924–40.
147.
KapoorMMcCannMLiuSHuhKDentonCPAbrahamDJLeaskA. Loss of peroxisome proliferator-activated receptor gamma in mouse fibroblasts results in increased susceptibility to bleomycin-induced skin fibrosis. Arthritis Rheum2009; 60: 2822–29.
148.
McCarthyKJRouthREShawWWalshKWelbourneTCJohnsonJH. Troglitazone halts diabetic glomerulosclerosis by blockade of mesangial expansion. Kidney Int2000; 58: 2341–50.
149.
KonKIkejimaKHiroseMYoshikawaMEnomotoNKitamuraT. Pioglitazone prevents early-phase hepatic fibrogenesis caused by carbon tetrachloride. Biochem Biophys Res Commun2002; 291: 55–61.
150.
WuMMelichianDSChangEWarner-BlankenshipMGhoshAKVargaJ. Rosiglitazone abrogates bleomycin-induced scleroderma and blocks profibrotic responses through peroxisome proliferator-activated receptor-gamma. Am J Pathol2009; 174: 519–33.
151.
WeiJGhoshAKSargentJLKomuraKWuMHuangQQJainMWhitfieldMLFeghali-BostwickCVargaJ. PPARγ downregulation by TGFß in fibroblast and impaired expression and function in systemic sclerosis: a novel mechanism for progressive fibrogenesis. PLoS One2010; 5: e13778–e13778.
152.
MutluGMBudingerGRWuMLamAPZirkARiveraSUrichDChiarellaSEGoLHGhoshAKSelmanMPardoAVargaJKampDWChandelNSSznajderJIJainM. Proteasomal inhibition after injury prevents fibrosis by modulating TGF-β(1) signalling. Thorax2012; 67: 139–46.
153.
PujolsLFernández-BertolínLFuentes-PradoMAlobidIRoca-FerrerJAgellNMullolJPicadoC. Proteasome inhibition reduces proliferation, collagen expression, and inflammatory cytokine production in nasal mucosa and polyp fibroblasts. J Pharmacol Exp Ther2012; 343: 184–97.
154.
JainMBudingerGRLoAUrichDRiveraSEGhoshAKGonzalezAChiarellaSEMarksKDonnellyHKSoberanesSVargaJRadiganKAChandelNSMutluGM. Leptin promotes fibroproliferative acute respiratory distress syndrome by inhibiting peroxisome proliferator-activated receptor-γ. Am J Respir Crit Care Med2011; 183: 1490–8.
155.
SomasundaramKEl-DeiryWS. Tumor suppressor p53: regulation and function. Front Biosci2000; 5: d424–37.
156.
BradyCAAttardiLD. p53 at a glance. J Cell Sci2010; 123: 2527–32.
157.
KunzCPeblerSOtteJvon der AheD. Differential regulation of plasminogen activator and inhibitor gene transcription by the tumor suppressor p53. Nucleic Acids Res1995; 23: 3710–17.
158.
IotsovaVStehelinD. Down-regulation of fibronectin gene expression by the p53 tumor suppressor protein. Cell Growth Differ1996; 7: 629–34.
159.
AlexandrovaAIvanovAChumakovPKopninBVasilievJ. Changes in p53 expression in mouse fibroblasts can modify motility and extracellular matrix organization. Oncogene2000; 19: 5826–30.
160.
NacuNLuzinaIGHighsmithKLockatellVPochetuhenKCooperZAGillmeisterMPToddNWAtamasSP. Macrophages produce TGF-beta-induced (beta-ig-h3) following ingestion of apoptotic cells and regulate MMP14 levels and collagen turnover in fibroblasts. J Immunol2008; 180: 5036–44.
161.
DagherPCMaiEMHatoTLeeSYAndersonMDKarozosSCMangHEKnipeNLPlotkinZSuttonTA. The p53 inhibitor pifithrin-α can stimulate fibrosis in a rat model of ischemic acute kidney injury. Am J Physiol Renal Physiol2012; 302: F284–91.
162.
SuttonTAHatoTMaiEYoshimotoMKuehlSAndersonMMangHPlotkinZChanRJDagherPC. p53 is renoprotective after ischemic kidney injury by reducing inflammation. J Am Soc Nephrol2013; 24: 113–24.
163.
TraisterABreitmanIBar-LevEZvibelIHarelAHalpernZOrenR. Nicotinamide induces apoptosis and reduces collagen I and pro-inflammatory cytokines expression in rat hepatic stellate cells. Scand J Gastroenterol2005; 40: 1226–34.
164.
HuangWTVayalilPKMiyataTHagoodJLiuRM. Therapeutic value of small molecule inhibitor to plasminogen activator inhibitor-1 for lung fibrosis. Am J Respir Cell Mol Biol2012; 46: 87–95.
165.
Kuro-oMMatsumuraYAizawaHKawaguchiHSugaTUtsugiTOhyamaYKurabayashiMKanameTKumeE, Iwasaki H, Iida ANishikawaSNagaiRNabeshimaYI. Mutation of the mouse klotho gene leads to a syndrome resembling ageing. Nature1997; 390: 45–51.
166.
TakahashiYKuro-OMIshikawaF. Aging mechanisms. Proc Natl Acad Sci U S A2000; 97: 12407–18.
167.
Kuro-oM. Klotho in health and disease. Curr Opin Nephrol Hypertens2012; 21: 362–8.
168.
SatohMNagasuHMoritaYYamaguchiTPKanwarYSKashiharaN. Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol2012; 303: F1641–51.
169.
SembaRDCappolaARSunKBandinelliSDalalMCrastoCGuralnikJMFerrucciL. Plasma klotho and cardiovascular disease in adults. J Am Geriatr Soc2011; 59: 1596–601.
170.
SaitoYNakamuraTOhyamaYSuzukiTIidaAShiraki-IidaTKuro-oMNabeshimaYKurabayashiMNagaiR. In vivo klotho gene delivery protects against endothelial dysfunction in multiple risk factor syndrome. Biochem Biophys Res Commun2000; 276: 767–72.
171.
ChengXZhouQLinSWuR. Fosinopril and valsartan intervention in gene expression of Klotho, MMP-9, TIMP-1, and PAI-1 in the kidney of spontaneously hypertensive rats. Zhong Nan Da Xue Xue Bao Yi Xue Ban2010; 35: 1048–56.
172.
DoiSZouYTogaoOPastorJVJohnGBWangLShiizakiKGotschallRSchiaviSYoriokaNTakahashiMBoothmanDAKuro-oM. Klotho inhibits transforming growth factor-beta1 (TGF-beta1) signaling and suppresses renal fibrosis and cancer metastasis in mice. J Biol Chem2011; 286: 8655–65.
173.
SugiuraHYoshidaTShiohiraSKoheiJMitobeMKurosuHKuro-oMNittaKTsuchiyaK. Reduced Klotho expression level in kidney aggravates renal interstitial fibrosis. Am J Physiol Renal Physiol2012; 302: F1252–64.
174.
SatohMNagasuHMoritaYYamaguchiTPKanwarYSKashiharaN. Klotho protects against mouse renal fibrosis by inhibiting Wnt signaling. Am J Physiol Renal Physiol2012; 303: F1641–51.
175.
WeiJFangFLamAPSargentJLHamburgEHinchcliffMEGottardiCJAtitRWhitfieldMLVargaJ. Wnt/β-catenin signaling is hyperactivated in systemic sclerosis and induces Smad-dependent fibrotic responses in mesenchymal cells. Arthritis Rheum2012; 64: 2734–45.
176.
YeBGeYPerensGHongLXuHFishbeinMCLiF. Canonical Wnt/β-catenin signaling in epicardial fibrosis of failed pediatric heart allografts with diastolic dysfunction. Cardiovasc Pathol2013; 22: 54–7.
177.
LamAPFlozakASRussellSWeiJJainMMutluGMBudingerGRFeghali-BostwickCAVargaJGottardiCJ. Nuclear β-catenin is increased in systemic sclerosis pulmonary fibrosis and promotes lung fibroblast migration and proliferation. Am J Respir Cell Mol Biol2011; 45: 915–22.
178.
ChengJHSheHHanYPWangJXiongSAsahinaKTsukamotoH. Wnt antagonism inhibits hepatic stellate cell activation and liver fibrosis. Am J Physiol Gastrointest Liver Physiol2008; 294: G39–49.
179.
LiuHFergussonMMCastilhoRMLiuJCaoLChenJMalideDRoviraIISchimelDKuoCJGutkindJSHwangPMFinkelT. Augmented Wnt signaling in a mammalian model of accelerated aging. Science2007; 317: 803–6.
180.
IyerNGOzdagHCaldasC. p300/CBP and cancer. Oncogene2004; 23: 4225–31.
181.
RoelfsemaJHWhiteSJAriyurekYBartholdiDNiedristDPapadiaFBacinoCAden DunnenJTvan OmmenGJBreuningMHHennekamRCPetersDJ. Genetic heterogeneity in Rubinstein-Taybi syndrome: mutations in both the CBP and EP300 genes cause disease. Am J Hum Genet2005; 76: 572–80.
182.
SahaRNPahanK. HATs and HDACs in neurodegeneration: a tale of disconcerted acetylation homeostasis. Cell Death Differ2006; 13: 539–50.
183.
MishraPKTyagiNKumarMTyagiSC. MicroRNAs as a therapeutic target for cardiovascular diseases. J Cell Mol Med2009; 13: 778–789.
184.
MannJChuDCMaxwellAOakleyFZhuNLTsukamotoHMannDA. MeCP2 controls an epigenetic pathway that promotes myofibroblast transdifferentiation and fibrosis. Gastroenterology2010; 138: 705–14.
GoodmanRHSmolikS. CBP/p300 in cell growth, transformation, and development. Genes Dev2000; 14: 1553–77.
187.
MorimotoTSunagawaYKawamuraTTakayaTWadaHNagasawaAKomedaMFujitaMShimatsuAKitaTHasegawaK. The dietary compound curcumin inhibits p300 histone acetyltransferase activity and prevents heart failure in rats. J Clin Invest2008; 118: 868–78.
188.
BradnerJEWestNGrachanMLGreenbergEFHaggartySJWarnowTMazitschekR. Chemical phylogenetics of histone deacetylases. Nat Chem Biol2010; 6: 238–43.
189.
NikiTRomboutsKDe BleserPDe SmetKRogiersVSchuppanDYoshidaMGabbianiGGeertsA. A histone deacetylase inhibitor, trichostatin A, suppresses myofibroblastic differentiation of rat hepatic stellate cells in primary culture. Hepatology1999; 29: 858–67.
190.
RomboutsKNikiTGreenwelPVandermondeAWielantAHellemansKDe BleserPYoshidaMSchuppanDRojkindMGeertsA. Trichostatin A, a histone deacetylase inhibitor, suppresses collagen synthesis and prevents TGF-beta(1)-induced fibrogenesis in skin fibroblasts. Exp Cell Res2002; 278: 184–97.
191.
GhoshAKMoriYDowlingEVargaJ. Trichostatin A blocks TGF-beta-induced collagen gene expression in skin fibroblasts: involvement of Sp1. Biochem Biophys Res Commun2007; 354: 420–6.
192.
WangJPWenMHChenYTLeeHHChiangERLeeYTLiuCLChenTHHungSC. Trichostatin A inhibits TGF-β1 induced in vitro chondrogenesis of hMSCs through Sp1 suppression. Differentiation2011; 81: 119–26.
193.
KaimoriAPotterJJChotiMDingZMezeyEKoteishAA. Histone deacetylase inhibition suppresses the transforming growth factor beta1-induced epithelial-to-mesenchymal transition in hepatocytes. Hepatology2010; 52: 1033–45.
194.
HuberLCDistlerJHMoritzFHemmatazadHHauserTMichelBAGayREMatucci-CerinicMGaySDistlerOJüngelA. Trichostatin A prevents the accumulation of extracellular matrix in a mouse model of bleomycin-induced skin fibrosis. Arthritis Rheum2007; 56: 2755–64.
195.
MarumoTHishikawaKYoshikawaMHirahashiJKawachiSFujitaT. Histone deacetylase modulates the proinflammatory and -fibrotic changes in tubulointerstitial injury. Am J Physiol Renal Physiol2010; 298: F133–41.
196.
PangMKothapallyJMaoHTolbertEPonnusamyMChinYEZhuangS. Inhibition of histone deacetylase activity attenuates renal fibroblast activation and interstitial fibrosis in obstructive nephropathy. Am J Physiol Renal Physiol2009; 297: F996–F1005.
197.
LiuFLevinMDPetrenkoNBLuMMWangTYuanLJStoutALEpsteinJAPatelVV. Histone-deacetylase inhibition reverses atrial arrhythmia inducibility and fibrosis in cardiac hypertrophy independent of angiotensin. J Mol Cell Cardiol2008; 45: 715–23.
198.
KongYTannousPLuGBerenjiKRothermelBAOlsonENHillJA. Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hyperetrophy. Circulation2006; 113: 2579–88.
199.
ChoYKEomGHKeeHJKimHSChoiWYNamKIMaJSKookH. Sodium valproate, a histone deacetylase inhibitor, but not captopril, prevents right ventricular hypertrophy in rats. Circ J2010; 74: 760–70.
200.
BogaardHJMizunoSHussainiAAToldoSAbbateAKraskauskasDKasperMNatarajanRVoelkelNF. Suppression of histone deacetylases worsens right ventricular dysfunction after pulmonary artery banding in rats. Am J Respir Crit Care Med2011; 183: 1402–10.
HuBGharaee-KermaniMWuZPhanSH. Essential role of MeCP2 in the regulation of myofibroblast differentiation during pulmonary fibrosis. Am J Pathol2011; 178: 1500–8.
204.
CowardWRWattsKFeghali-BostwickCAJenkinsGPangL. Repression of IP-10 by interactions between histone deacetylation and hypermethylation in idiopathic pulmonary fibrosis. Mol Cell Biol2010; 30: 2874–86.
205.
ThumTGrossCFiedlerJFischerTKisslerSBussenMGaluppoPJustSRottbauerWFrantzSCastoldiMSoutschekJKotelianskyVRosenwaldABassonMALichtJDPenaJTRouhanifardSHMuckenthalerMUTuschlTMartinGRBauersachsJEngelhardtS. MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts. Nature2008; 456: 980–4.
206.
RoySKhannaSHussainSRBiswasSAzadARinkCGnyawaliSShiloSNuovoGJSenCK. MicroRNA expression in response to murine myocardial infarction: miR-21 regulates fibroblast metalloprotease-2 via phosphatase and tensin homologue. Cardiovasc Res2009; 82: 21–9.
207.
ZarjouAYangSAbrahamEAgarwalALiuG. Identification of a microRNA signature in renal fibrosis: role of miR-21. Am J Physiol Renal Physiol2011; 301: F793–801.
208.
SinningARLeperaRCMarkwaldRR. Initial expression of type I procollagen in chick cardiac mesenchyme is dependent upon myocardial stimulation. Dev Biol1988; 130: 167–74.
209.
ArciniegasEServinMArgüelloCMotaM. Development of the aorta in the chick embryo: structural and ultrastructural study. Atherosclerosis1989; 76: 219–35.
210.
ArciniegasESuttonABAllenTDSchorAM. Transforming growth factor beta 1 promotes the differentiation of endothelial cells into smooth muscle-like cells in vitro. J Cell Sci1992; 103: 521–9.
TangRNLvLLZhangJD. Effects of angiotensin II receptor blocker on myocardial endothelial-to-mesenchymal transition in diabetic rats. Int J Cardiol2013; 162: 92–9.
222.
WhiteESMantovaniAR. Inflammation, wound repair, and fibrosis: reassessing the spectrum of tissue injury and resolution. J Pathol2013; 229: 141–4.
223.
JunJIILauLF. The matricellular protein CCN1/CYR61 induces fibroblast senescence and restricts fibrosis in cutaneous wound healing. Nat Cell Biol2010; 12: 676–85.
224.
KongXFengDWangH. Interleukin-22 induces hepatic stellate cell senescence and restricts liver fibrosis in mice. Hepatology2012; 56: 1150–9.
